Odyssey Therapeutics Reports Q3 Net Loss of $53.10 Million

Odyssey Therapeutics reported third-quarter 2026 revenue of $0 down from $99K a year earlier, and a net loss attributable to common stockholders of $53.1M, compared with a $35.5M loss in the prior-year quarter. Diluted EPS was $(1.10), versus $(7.78).Financial HighlightsBusiness HighlightsOriginal…